In a letter to the Chairman and Ranking Member of the United States Senate Committee on Health, Education, Labor and Pensions (HELP), the Sarcoma Foundation of America (SFA) expressed support for the nomination of Scott Gottlieb, MD, for Commissioner of the Food and Drug Administration. In the letter, the SFA urged for the conformation of Dr. Gotlieb, writing that “Dr. Gottleib has an exemplary track record of supporting and spearheading efforts to ensure that safe and effective treatments are moved through the review process in an expedient manner. During his tenure as the Deputy Commissioner for Medical and Scientific Affairs at the FDA, Dr. Gottlieb championed the need for the FDA to be efficient and patient-focused in its job of evaluating new therapies. This prior experience at the FDA and his efforts to increase efficiency through the Critical Path Initiative demonstrate his ability to improve the FDA through thoughtful, science-driven reforms. For these efforts, the SFA honored Dr. Gottlieb in 2007 with our Visionary in Medicine Award.”
A confirmation hearing for Dr. Gottlieb is scheduled for Wednesday, March 5, 2017. Information on the hearing can be found at https://www.help.senate.gov/hearings/nomination-of-scott-gottlieb-md-to-serve-as-commissioner-of-food-and-drugs.